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The US National Institutes of Health (NIH) guidelines
for treating asthma classify patients into four severity lev-
els (severe persistent, moderate persistent, mild persis-
tent, and mild intermittent) based largely on clinically as-
sessed symptoms and physical measurements such as
forced expiratory volume. The guidelines also recom-
mend specific regimens of various asthma medications
for each severity level. OBJECTIVE: To use the medica-
tion regimens recommended by NIH to classify asthma
severity based on patterns of drug use in prescription
claims. METHODS: Using claims data from a large
health insurer in the Northeast US, study patients were
selected in part on the basis of having used zafirlukast
continuously at some point during the 30 months cov-
ered by the database. Of the 780 study patients, 76.8%
could be classified by a computer program into one of the
four NIH severity categories based on their patterns of
asthma drug use as specified in the NIH guidelines. The
remaining 23.2% were classified through review of indi-
vidual claim histories by a nurse abstractor. RESULTS:
60.9% of study patients were classified as having mild
persistent asthma, 22.6% were moderate persistent, 10.4%
were severe persistent, and 6.2% were mild intermittent.
The nurse abstractor also performed a blind review of the
claim histories for a 15% sample of patients who had
been programmatically classified. The two classifications
disagreed in only six cases (i.e., 93.3% agreement, kappa 
0.885, P  0.001). CONCLUSION: Asthma patients can
be classified by severity level based on drug use patterns
in prescription claims with an acceptable level of validity
based on clinical review. This methodology could facilitate
efficient monitoring of asthma severity levels within pa-
tient populations.
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COPD is known to be an underdiagnosed condition.
Stage of disease is an important predictor of diagnosis of
COPD. Previous work has demonstrated that disease
stage, age, gender, race, smoking, cough, and breathless-
ness are drivers of diagnosis for obstructive lung disease
[Coultas et al, ERS 1999]. OBJECTIVES: The purpose of
the study was to determine whether different attributes
or symptoms were responsible for diagnosis at different
stages of disease. METHODS: The US National Health
and Nutrition Examination Survey conducted 1988–1994
measured pulmonary function, respiratory symptoms and
self-reported diagnosis on a representative sample of the
US population. Stage was defined using spirometry, by
ATS definitions. Physical functioning, symptoms ques-
tions, age, gender, race and smoking history were in-
cluded as potential predictors of diagnosis. RESULTS:
Only 19% of individuals with spirometry-defined COPD
reported a history of diagnosed disease. Presence of 2 or
more symptoms (cough, phlegm, sob, wheeze) was the
only indicator which remained in the model for all stages.
The overall OR was 17.5 (11.8, 26.0) Race was highly
significant, OR 20.6 (1.8, 229.3), but only at stage 3.
Physical functioning was significant only in the univari-
ate analysis. CONCLUSIONS: These findings suggest
that symptoms alone are prompting diagnoses of COPD
at all levels of disease. But this population demonstrates
that when disease is defined by spirometry, only a small
proportion of individuals with COPD are actually being
diagnosed.
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Inhaled corticosteroids have revolutionized the treatment
of asthma and have now become the mainstay of therapy
for patients with chronic disease. OBJECTIVE: The pri-
mary objective was to determine the relationship between
inhaled steroid use patterns and asthma-related total
health care cost (e.g. as hospitalizations, emergency room
visits, and pharmacy cost) from a managed care perspec-
tive. METHODS: Retrospective computerized claims
records from a large managed care organization were an-
alyzed. Patients were included if they had an IDC-9 diag-
nosis code for asthma (493.xx) and received at least 1 in-
haled beta agonist during a 3 month identification
period. Patients who received a steroid inhaler during the
identification period were included in the treatment
group and those who never received a steroid inhaler
were included in the control group. All patients were fol-
lowed for a 1 year period, but were excluded if they were
not continuously enrolled in the health plan. RESULTS:
Patients who received a steroid inhaler had a higher phar-
macy cost compared to those who did not ($453 versus
$894, P  0.001). In a multivariate regression analysis
controlling for potential confounding factors such as age,
gender, benefit design, disease severity, and number of
comorbidities, pharmacy cost remained higher in the ste-
roid inhaler group (Beta  $428, P  0.0001). In a simi-
lar regression analysis, total health care cost was lower in
the steroid inhaler group (Beta  $1,892, P  0.001).
Furthermore, the use of steroid inhalers was associated
with less utilization of methylprednisolone dose packs.
CONCLUSION: The higher cost of inhaled steroid use
appears to be offset by a reduction in hospital and emer-
gency room visit cost.
